Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380238 | 0.82 | MAPKAPK2 (0.46) | CDC7JAK2ROCK2MAP4K4PRKACA | |
| SCHEMBL8437346 | 0.74 | CSNK1D (0.43) | CDC7JAK2ROCK2MAP4K4PRKACA | |
| SCHEMBL5383014 | 0.73 | CSNK1D (0.42) | CDC7JAK2ROCK2MAP4K4PRKACA | |
| SCHEMBL5374948 | 0.73 | KDR (0.43) | CDC7JAK2ROCK2MAP4K4PRKACA | |
| SCHEMBL5381806 | 0.72 | JAK2 (0.48) | JAK2ROCK2DYRK1AMAPK1CSNK1D | |
| SCHEMBL5372967 | 0.71 | CSNK1D (0.64) | CDC7JAK2ROCK2MAP4K4PRKACA | |
| SCHEMBL5381891 | 0.71 | CSNK1D (0.44) | CDC7JAK2ROCK2MAP4K4PRKACA | |
| SCHEMBL5386736 | 0.70 | CSNK1D (0.45) | CDC7JAK2ROCK2MAP4K4PRKACA | |
| SCHEMBL5377949 | 0.70 | CSNK1D (0.54) | CDC7JAK2ROCK2MAP4K4PRKACA | |
| SCHEMBL5387313 | 0.69 | CSNK1D (0.52) | GSK3BCLK4DYRK1ANTRK1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | claimed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | claimed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | CDC7 1480/4885JAK2 123/4885ROCK2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.